About AngioScore
AngioScore is a company based in Fremont (United States) founded in 2003 was acquired by Spectranetics GSM in May 2014. AngioScore has raised $87 million across 4 funding rounds from investors including Spectranetics GSM, Saints Capital and Psilos Group. AngioScore operates in a competitive market with competitors including Contego Medical, Echopoint Medical, Limflow, Vascular Solutions and ev3 Endovascular, among others.
- Headquarter Fremont, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Angioscore Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$87 M (USD)
in 4 rounds
-
Latest Funding Round
$12 M (USD), Series E
Apr 26, 2011
-
Investors
Spectranetics GSM
& 6 more
-
Employee Count
Not available
-
Acquired by
Spectranetics GSM
(May 27, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of AngioScore
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of AngioScore
AngioScore has successfully raised a total of $87M across 4 strategic funding rounds. The most recent funding activity was a Series E round of $12 million completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AngioScore
AngioScore has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Spectranetics GSM, Saints Capital and Psilos Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Direct secondary investments are made in private company shares.
|
Locked | Locked | Locked | |
|
Growth-stage investments focused on US tech and life sciences.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science, medical device and healthcare companies
|
Locked | Locked | Locked |
Investor details for AngioScore
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AngioScore
Investment portfolio details for AngioScore
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AngioScore
Detailed financials for AngioScore
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Angioscore Comparisons
Peer comparison for AngioScore
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AngioScore
AngioScore operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Contego Medical, Echopoint Medical, Limflow, Vascular Solutions and ev3 Endovascular, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of vascular stenting with embolic protection for both coronary and peripheral vasculature
|
|
| Locked | Locked | Locked |
Smart devices for monitoring coronary artery disease are developed.
|
|
| Locked | Locked | Locked |
Developer a system for venous arterialization of the lower limbs
|
|
| Locked | Locked | Locked |
Products for vascular diagnostics and interventional procedures are developed.
|
|
| Locked | Locked | Locked |
Surgical products for treatment of Peripheral vascular & Neurovascular diseases
|
Detailed competitors of AngioScore
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Angioscore
Complete news archive for AngioScore
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AngioScore
AngioScore was founded in 2003 and raised its 1st funding round 1 year after it was founded.
AngioScore is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
AngioScore is a funded company, having raised a total of $87M across 4 funding rounds to date.
AngioScore was founded in 2003 as an Israeli-American startup focused on medical devices for cardiovascular treatments. The AngioSculpt Scoring Balloon Catheter was created to address coronary and peripheral artery diseases through angioplasty procedures. Regulatory approvals, including CE marking and FDA clearance, were secured for these products. The company was acquired by Spectranetics in June 2014, with operations centered in Fremont, United States.
AngioScore's top competitors include Contego Medical, Limflow and Shape Memory Medical.
AngioScore has 7 investors. Key investors include Spectranetics GSM, Saints Capital, Psilos Group, Telegraph Hill Partners, and QuestMark Partners.